Eighteen patients with LMD underwent VPS placement and Ommaya reservoir for intrathecal chemotherapy. Eleven patients had breast cancer, four had lung cancer, and the remaining three patients had thyroid, esophageal and uterine cancer respectively. Seventeen patients are deceased, and one patient was lost to follow up, and not included in our analysis. Sixteen (94%) patients had brain metastases. Eleven patients (61.1%) received radiotherapy prior to VPS placement. Karnofsky scores ranged from 60 to 90. Seven (41%) patients did not receive intrathecal chemotherapy due to rapid LMD progression. Ten (59%) patients received intrathecal Topotecan, and one received Cytarabine at the time of disease progression. The overall survival of these patients from time of VPS placement was 15.15 weeks (range 4.1-203.2), of which seven (41%) survived less than eight weeks. Six (60%) patients died from LMD progression, three (30%) from systemic disease progression, and one (10%) died of medical complications.